Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at ...
CervoMed to present 32-week results from its Phase 2b RewinD-LB study in dementia with Lewy bodies on July 28, 2025. CervoMed Inc. will host a conference call and webcast on July 28, 2025, at 8:00 AM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results